Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary

Key facts

Sponsor

Eastern Cooperative Oncology Group

Principal Investigator

Victor T. Chang, MD, D.M.D

Veterans Affairs Medical Center - East Orange

Intervention

gemcitabine hydrochloride(drug)

Enrollment

52 enrolled

Eligibility

18-120 years · All sexes

Timeline

2006

Study locations (30)

• University of Illinois Cancer Center, Chicago, Illinois, United States
• Veterans Affairs Medical Center - Chicago Westside Hospital, Chicago, Illinois, United States
• Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
• Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States
• Regional Cancer Center at Memorial Medical Center, Springfield, Illinois, United States
• Elkhart General Hospital, Elkhart, Indiana, United States
• Howard Community Hospital, Kokomo, Indiana, United States
• Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States
• CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
• Memorial Hospital of South Bend, South Bend, Indiana, United States
• Saint Joseph Regional Medical Center, South Bend, Indiana, United States
• McFarland Clinic, PC, Ames, Iowa, United States
• Borgess Medical Center, Kalamazoo, Michigan, United States
• West Michigan Cancer Center, Kalamazoo, Michigan, United States
• Bronson Methodist Hospital, Kalamazoo, Michigan, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cancer of unknown primary site

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07524114
  Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
  University Health Network, Toronto
• RECRUITINGNANCT07283939
  Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
  Alliance for Clinical Trials in Oncology
• RECRUITINGPHASE2NCT06995508
  Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
  Roswell Park Cancer Institute
• RECRUITINGPHASE1NCT06868433
  TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
  Emory University
• RECRUITINGPHASE3NCT06589804
  Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
  National Cancer Institute (NCI)
• RECRUITINGNANCT06662058
  Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
  Emory University
• RECRUITINGPHASE2NCT06636734
  Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
  Emory University
• RECRUITINGNANCT06644716
  [18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
  Erasmus Medical Center

See all trials for Cancer of unknown primary site →